Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 27 citing articles:

GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
Kallirhoe Kalinderi, Vasileios Papaliagkas, Liana Fidani
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3812-3812
Open Access | Times Cited: 18
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Nirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
The Lancet (2025)
Open Access | Times Cited: 10
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 3
Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach
Davide Arillotta, Giuseppe Floresta, Guy Pelletier, et al.
Brain Sciences (2024) Vol. 14, Iss. 6, pp. 617-617
Open Access | Times Cited: 15
Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists
Alla A. Boshchenko, Л. Н. Маслов, А. V. Mukhomedzyanov, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4900-4900
Open Access | Times Cited: 12
IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Nicolaus Bruns, Elizabeth H. Tressler, Leandro F. Vendruscolo, et al.
Pharmacological Research (2024) Vol. 207, pp. 107312-107312
Open Access | Times Cited: 10
Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs?
Rodrigo B. Mansur, Joshua D. Di Vincenzo, Sebastian Badulescu, et al.
CNS Spectrums (2025), pp. 1-6
Closed Access | Times Cited: 1
Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
Lívia Cristina Ribeiro Teixeira, Marcelo R. Luizon, Karina Braga Gomes
Receptors (2025) Vol. 4, Iss. 1, pp. 2-2
Open Access | Times Cited: 1
Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
Wenchao Lu, Shihan Wang, Huilin Tang, et al.
European Psychiatry (2025) Vol. 68, Iss. 1
Open Access | Times Cited: 1
Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Ageing Research Reviews (2024) Vol. 98, pp. 102343-102343
Closed Access | Times Cited: 8
Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP/PS1 mice
Shaobin Yang, Xiaoqian Zhao, Yimeng Zhang, et al.
Peptides (2024) Vol. 179, pp. 171271-171271
Closed Access | Times Cited: 8
The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications
William A. Banks, Elizabeth M. Rhea, May J. Reed, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 11, pp. 101760-101760
Open Access | Times Cited: 6
The antiemetic actions of GIP receptor agonism
Tito Borner, Bart C. De Jonghe, Matthew R. Hayes
AJP Endocrinology and Metabolism (2024) Vol. 326, Iss. 4, pp. E528-E536
Closed Access | Times Cited: 5
All GLP-1 Agonists Should, Theoretically, Cure Alzheimer’s Dementia but Dulaglutide Might Be More Effective Than the Others
Jeffrey Fessel
Journal of Clinical Medicine (2024) Vol. 13, Iss. 13, pp. 3729-3729
Open Access | Times Cited: 4
Vers un traitement neuroprotecteur dans la MPI ? La cible GLP-1
Wassilios G. Meissner
Pratique Neurologique - FMC (2025)
Closed Access
Tirzepatide reduces body weight by increasing fat utilization via the central nervous system‐adipose tissue axis in male mice
Ailin Zhang, Qinhui Liu, Yimin Xiong, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Dipeptidyl peptidase-4 inhibitors enhance memory retention via neuropeptide Y
Iulia Zoicas, Stephan von Hörsten, Anne-Christine Plank, et al.
European Journal of Pharmacology (2025), pp. 177556-177556
Open Access
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Riccardo De Giorgi, Ana Ghenciulescu, Courtney Yotter, et al.
Journal of Neurology Neurosurgery & Psychiatry (2025), pp. jnnp-335593
Closed Access
Incretin-based therapeutics for the treatment of neurodegenerative diseases
Anika Vear, Michael T. Heneka, Christoffer Clemmensen
Nature Metabolism (2025)
Closed Access
Why do obesity drugs seem to treat so many other ailments?
Mariana Lenharo
Nature (2024) Vol. 633, Iss. 8031, pp. 758-760
Closed Access | Times Cited: 3
Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease
Dong-Jun Lv, Peng Feng, Xueying Guan, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 3
Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration
Katherine O. Kopp, Yazhou Li, Elliot J. Glotfelty, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 872-872
Open Access | Times Cited: 2
Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP/PS1/tau mice
Zhaojun Wang, Wei-Na Han, Shi-Fan Chai, et al.
Neuroscience (2024) Vol. 563, pp. 222-234
Closed Access | Times Cited: 2
Special Issue “Pathophysiology and Treatment of Alzheimer’s Disease”
Jeffrey Fessel
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6015-6015
Open Access | Times Cited: 1
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity
Robert H. Gaffey, Afua K. Takyi, Alpana P. Shukla
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 8, pp. 757-773
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top